Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Respiratory disease is a medical condition that affects the structure and organs associated with respiration or breathing. Based on anatomical features, the respiratory system has been segmented into upper respiratory tract and lower respiratory tract. The upper respiratory tract comprises pharynx, larynx and nasal passages, while the lower respiratory tract includes trachea, lungs and bronchi.

Statistics:

The global respiratory disease testing market is estimated to account for US$ 3,738.8 Mn in terms of value by the end of 2027.

Global Respiratory Disease Testing Market: Drivers

Increasing prevalence of respiratory diseases is expected to propel growth of the global respiratory disease testing market over the forecast period. For instance, according to a report by Global Initiative For Chronic Obstruction Disease’s 2018 report, COPD is expected to result in 4.5 million global deaths annually by 2030.

Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the World Health Organization, geriatric population is expected to reach 2 billion by 2050, up from 900 million in 2015.    

Statistics:

North America held dominant position in the global respiratory disease testing market in 2019, accounting for 34.6% share in terms of value, followed by Asia Pacific and Europe, respectively.

Figure 1: Global Respiratory Disease Testing Market Share (%) Value, By Region, 2019

Respiratory Disease Testing  | Coherent Market Insights

Global Respiratory Disease Testing Market: Restraints

Low adoption rate of digital radiography is expected to hinder the market growth. Digital radiography systems have witnessed low adoption rate as these are more expensive than analog radiography systems (US$ 11,000 – US$ 22,000). The cost of digital radiography equipment ranges from US$ 100,000 to US$ 130, 000.

Moreover, inaccuracy of rapid diagnostic tests is also expected to hinder growth of the market. For instance, in May 2020, a study by researchers at New York University found that a COVID-19 rapid diagnostic made by Abbott Laboratories failed to detect up to 48% of positive results.

request-sample

Respiratory Disease Testing Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 2,831.0  Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 3.5% 2027 Value Projection: US$ 3,738.8 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe
  • Asia Pacific: China, Japan, India, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: North Africa, Central Africa, South Africa
Segments covered:
  • By Test Type: Imaging Test, Spirometer, Peak Flow Test, Blood Gas Test, Lung Volume Test, Others.
  • By End User: Hospitals, Physician Offices, Clinical Laboratories.
Companies covered:

CareFusion Corporation, Carestream Health, Inc., COSMED, Futuremed America, Inc., GE Healthcare, MGC Diagnostics Corporation, ndd Medical Technologies, Inc., Nihon Kohden Corporation, Perkin Elmer, Inc., Philips Healthcare, and Quest Diagnostics.

Growth Drivers:
  • Increasing prevalence of respiratory disorders
  • Approval and launch of new products
Restraints & Challenges:
  • Product recall

Global Respiratory Disease Testing Market: Opportunities  

Increasing prevalence of lung cancer is expected to offer lucrative growth opportunities for players in the global respiratory disease testing market. For instance, according to The American Cancer Society, in 2020, the U.S. is expected to witness around 228,820 new cases of lung cancer and around 135,720 deaths due to the disease.

Moreover, increasing number of smokers is also expected to aid in growth of the market. For instance, according to the World Health Organization, 1.337 billion people smoked tobacco worldwide in 2018.     

Statistics:

The global respiratory disease testing market was valued at US$ 2,831.0 Mn in 2019 and is forecast to reach a value of US$ 3,738.8 Mn by 2027 at a CAGR of 3.5% between 2020 and 2027.

Figure 2: Global Respiratory Disease Testing Market Value (US$ Mn), 2016 – 2027

Respiratory Disease Testing  | Coherent Market Insights

Market Trends/Key Takeaways

Increasing air pollution is boosting growth of the market. For instance, according to Health Effects Institute estimates (provided by University of Texas at Austin), air pollution was the fifth leading risk factor for mortality worldwide in 2019.

Major players in the market are focused on launching new products to expand their product portfolio. For instance, in March 2020, Quest Diagnostics announced to launch a coronavirus (COVID-19) test service that aids the presumptive detection of nucleic acid in respiratory specimens of patients meeting the Centers for Disease Control and Prevention’s clinical criteria for COVID-19 testing.

Regulations

Occupational Safety and Health Administration (OSHA), the U.S. Department of Labor, stated in 2013 that healthcare professionals conducting occupational spirometry testing should complete initial lung function testing course approved by National Institute for Occupational Safety and Health (NIOSH). It also recommended that a lung function testing equipment should have the following features: meet accuracy and precision criteria set by American Thoracic Society/European Respiratory Society and instrument should have real time graphical display.

Global Respiratory Disease Testing Market: Competitive Landscape

Major players operating in the global respiratory disease testing market include, CareFusion Corporation, Carestream Health, Inc., COSMED, Futuremed America, Inc., GE Healthcare, MGC Diagnostics Corporation, ndd Medical Technologies, Inc., Nihon Kohden Corporation, Perkin Elmer, Inc., Philips Healthcare, and Quest Diagnostics.

Global Respiratory Disease Testing Market: Key Developments

Major players in the market are focused on launching new products to expand their product portfolio. For instance, in June 2020, Carestream Health, Inc. launched Carestream NDT INDUSTREX Digital Viewing Software Version 5.2, a non-destructive testing (NDT) technology.

The respiratory system is divided into two parts; upper respiratory tract and lower respiratory tract. The upper respiratory tract includes pharynx, larynx and nasal passages, while the lower respiratory tract includes trachea, lungs and bronchi. Respiratory Disease Testing is carried out for diagnosis of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and pneumonia. Increasing product approvals, increasing prevalence of respiratory disorders in developed and developing economies along with increasing technological advancements in product development.

Key features of the study:

  • This report provides in-depth analysis of the Global Respiratory Disease Testing market  and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the Global Respiratory Disease Testing market  based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, CareFusion Corporation, Carestream Health, Inc., COSMED, Futuremed America, Inc., GE Healthcare, MGC Diagnostics Corporation, ndd Medical Technologies, Inc., Nihon Kohden Corporation, Perkin Elmer, Inc., Philips Healthcare, and Quest Diagnostics.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The Global Respiratory Disease Testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Respiratory Disease Testing market

Detailed Segmentation:

  • Global Respiratory Disease Testing Market, By Test Type:
    • Imaging Test
    • Spirometry
    • Peak Flow Test
    • Blood Gas Test
    • Lung Volume Test
    • Others
  • Global Respiratory Disease Testing Market, By End User:
    • Hospitals
    • Physician Offices
    • Clinical Laboratories
  • Global Respiratory Disease Testing Market, By Region:
    • North America
      • By Test Type:
        • Imaging Test
        • Spirometry
        • Peak Flow Test
        • Blood Gas Test
        • Lung Volume Test
        • Others
      • By End User
        • Hospitals
        • Physician Offices
        • Clinical Laboratories
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Test Type:
        • Imaging Test
        • Spirometry
        • Peak Flow Test
        • Blood Gas Test
        • Lung Volume Test
        • Others
      • By End User
        • Hospitals
        • Physician Offices
        • Clinical Laboratories
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Test Type:
        • Imaging Test
        • Spirometry
        • Peak Flow Test
        • Blood Gas Test
        • Lung Volume Test
        • Others
      • By End User
        • Hospitals
        • Physician Offices
        • Clinical Laboratories
      • By Country
        • U.K.
        • Germany
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Test Type:
        • Imaging Test
        • Spirometry
        • Peak Flow Test
        • Blood Gas Test
        • Lung Volume Test
        • Others
      • By End User
        • Hospitals
        • Physician Offices
        • Clinical Laboratories
      • By Country
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Test Type:
        • Imaging Test
        • Spirometry
        • Peak Flow Test
        • Blood Gas Test
        • Lung Volume Test
        • Others
      • By End User
        • Hospitals
        • Physician Offices
        • Clinical Laboratories
      • By Country
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • By Test Type:
        • Imaging Test
        • Spirometry
        • Peak Flow Test
        • Blood Gas Test
        • Lung Volume Test
        • Others
      • By End User
        • Hospitals
        • Physician Offices
        • Clinical Laboratories
      • By Country
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
    • CareFusion Corporation *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Strategies
    • Carestream Health, Inc.
    • COSMED
    • Futuremed America, Inc.
    • GE Healthcare
    • MGC Diagnostics Corporation
    • ndd Medical Technologies, Inc.
    • Nihon Kohden Corporation
    • Perkin Elmer, Inc.
    • Philips Healthcare
    • Quest Diagnostics
  • “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Test Type
      • Market Snippet, By End User
      • Market Snippet, By Country
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Highlights
    • Product launch
    • PEST Analysis
    • Technological Advancements
    • Regulatory Scenario
    • Mergers and Acquisitions
    • Impact of COVID19 on market
  4. Global Respiratory Disease Testing Market, By Test Type, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Imaging Test
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Spirometry
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Peak Flow Test
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Blood Gas Test
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Lung Volume Test
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  5. Global Respiratory Disease Testing Market, By End User, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Physician Offices
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Clinical Laboratories
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Respiratory Disease Testing Market, By Region, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  7. Competitive Landscape
    • Company Profiles
      • CareFusion Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Carestream Health, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • COSMED
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Futuremed America, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GE Healthcare
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • MGC Diagnostics Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • ndd Medical Technologies, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Nihon Kohden Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • PerkinElmer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Philips Healthcare
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Quest Diagnostics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 26 market data tables and 18 figures on “Respiratory Disease Testing Market - Global forecast to 2027”.

Frequently Asked Questions

The Global Respiratory Disease Testing market size was valued at US$ 2,831.0 million in 2019 and is estimated to exhibit a CAGR of 3.5% between 2020 and 2027.
Imaging Test segment held the major market share in 2019 owing increasing prevalence of respiratory disorders on developing ecnomies is expected to propel growth of the global Respiratory Disease Testing market over the forecast period.
Major factor driving the growth of Global Respiratory Disease Testing market during the forecast period increasing prevalence of respiratory diseases, increasing healthcare infrastructure, new product launch , and adoption of expansion strategies from major companies.
Major factors hampering the growth of the Global Respiratory Disease Testing market during the forecast period constitutes of product recalls and lack of efficient rapid testing devices.
North America market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are CareFusion Corporation, Carestream Health, Inc., COSMED, Futuremed America, Inc., GE Healthcare, MGC Diagnostics Corporation, ndd Medical Technologies, Inc., Nihon Kohden Corporation, Perkin Elmer, Inc., Philips Healthcare, and Quest Diagnostics.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner